IP Library Granted Patent US 10,220,011
Granted Patent B2
US 10,220,011 · App. 15/720,849 · Granted Mar 5, 2019

Treatment of intrahepatic cholestatic diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,011
App. No.
15/720,849
Granted
Mar 5, 2019
Kind
B2
Abstract

Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

Claims (9)

1. A method of treating progressive familial intrahepatic cholestasis by administering to a subject in need thereof a therapeutically effective amount of a compound that is (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof.

2. The method of claim 1 where the compound is administered orally.

3. The method of claim 1 where the daily dose of the compound is 20-200 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

4. The method of claim 3 where the daily dose of the compound is 50-100 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

5. The method of claim 4 where the compound is administered once/day.

6. A method of treating progressive familial intrahepatic cholestasis by orally administering to a subject in need thereof a therapeutically effective amount of a compound that is (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L-lysine dihydrate salt.

7. The method of claim 6 where the daily dose of the compound is 20-200 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

8. The method of claim 7 where the daily dose of the compound is 50-100 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

9. The method of claim 6 where the compound is administered once/day.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Oct 3, 2024
From: ABW CYCLOPS SPV LP
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 069833/0155 →